Notably, administration of INGAPpp, a pentadecapeptide derived from hamster REG3A, has been shown to increase islet volume and cell mass in diabetic models, preventing streptozotocin (STZ)-induced diabetes without directly stimulating cell proliferation [99,105]. Here, REG3A is linked to diabetes mellitus.